Millennium Group reports 5.3% stake in Cabaletta Bio
Cabaletta Bio, Inc. Schedule 13G reports that Millennium Management LLC, together with Millennium Group Management LLC and Israel A. Englander, beneficially hold 5,130,763 shares of common stock, representing 5.3% of the class.
Rhea-AI Filing Summary
Cabaletta Bio, Inc. Schedule 13G reports that Millennium Management LLC, together with Millennium Group Management LLC and Israel A. Englander, beneficially hold 5,130,763 shares of common stock, representing 5.3% of the class.
The filing states the holders report shared voting power and shared dispositive power over the 5,130,763 shares and includes a Joint Filing Agreement dated February 17, 2026.
Positive
- None.
Negative
- None.
Insights
Joint filing shows coordinated disclosure of a 5.3% stake.
The filing lists shared voting power and shared dispositive power over 5,130,763 shares as reported on the cover pages. The owners executed a Joint Filing Agreement dated February 17, 2026.
Implications depend on future amendments or schedules disclosing changes; subsequent filings would show any change in voting or disposition rights.
A 5.3% position is a notable passive holding but not a controlling stake.
The disclosed 5,130,763 shares equals 5.3% of the class according to Item 11 on the cover pages. The reporting persons disclaim construing that figure as an admission of beneficial ownership beyond the disclosed voting/dispositive powers.
Market impact will depend on whether these holders buy, sell, or file different schedules in the future; timing and cash‑flow treatment are not stated here.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Millennium report in Cabaletta Bio (CABA)?
Who filed the Schedule 13G for CABA?
Is the reported ownership in CABA admitted as beneficial ownership?
What agreement among the filers is included in the CABA filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.